These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 159512)

  • 1. The plasminogen content of commercial preparations and of normal donor plasma in relation to the plasmin content of the 1st international plasmin reference preparation.
    Wolf P
    Thromb Haemost; 1979 Aug; 42(2):582-95. PubMed ID: 159512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the reliability of plasminogen measurement employing the proactivator-activator converting method.
    Martin M
    Thromb Haemost; 1976 Dec; 36(3):551-65. PubMed ID: 138961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International collaborative study for the establishment of the second International Reference Preparation of plasmin.
    Gaffney PJ; Mussett MV
    Thromb Haemost; 1983 Oct; 50(3):645-9. PubMed ID: 6228030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the effect of plasminogen activator on the interaction between alpha 2-macroglobulin and plasmin.
    Toki N; Takasugi S; Sumi H; Yamura T
    Thromb Haemost; 1978 Oct; 40(2):377-86. PubMed ID: 83685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine and its thiolactone impair plasmin activity induced by urokinase or streptokinase in vitro.
    Kolodziejczyk-Czepas J; Talar B; Nowak P; Olas B; Wachowicz B
    Int J Biol Macromol; 2012 Apr; 50(3):754-8. PubMed ID: 22197896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of endogenous fibrinolysis activation on human plasminogen].
    Platonova TK; Kalashnikov VV; Khvatov VB
    Biull Eksp Biol Med; 1987 Jan; 103(1):59-61. PubMed ID: 2432967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition by ethanol and acetaldehyde the plasmin activity and plasminogen activation induced by urokinase and streptokinase].
    Roszkowska-Jakimiec W; Jurkowski J; Ostrowska H; Worowski K
    Rocz Akad Med Bialymst (1989); 1988-1989; 33-34():53-66. PubMed ID: 2979011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA).
    Gaffney PJ; Heath AB
    Thromb Haemost; 1990 Nov; 64(3):398-401. PubMed ID: 2128969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation of a novel streptokinase mutant with improved stability.
    Shi GY; Chang BI; Su SW; Young KC; Wu DH; Chang LC; Tsai YS; Wu HL
    Thromb Haemost; 1998 May; 79(5):992-7. PubMed ID: 9609235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.
    Liotta LA; Goldfarb RH; Brundage R; Siegal GP; Terranova V; Garbisa S
    Cancer Res; 1981 Nov; 41(11 Pt 1):4629-36. PubMed ID: 6458354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of commercially available plasminogen preparations in vitro: purity and reactivity.
    Miyashita C; Heiden M; Leipnitz G; Pindur G; Wenzel E
    Haemostasis; 1988; 18 Suppl 1():121-6. PubMed ID: 3350393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A method for the measurement of fibrinolytic activity based on one dimensional diffusion using small glass tubes. II. With special reference to the differences between the use of plasminogen-rich fibrinogen and that of plasminogen-free fibrinogen as the substrates.
    Yasukouchi T; Fujine M; Kohn S; Sakurama S; Morioka T
    Thromb Haemost; 1977 Jun; 37(3):456-63. PubMed ID: 578026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The isolation and characterization of a ternary human plasmin B-chain-streptokinase-plasminogen complex.
    Summaria L; Boreisha I; Barlow GH; Robbins KC
    Thromb Haemost; 1987 Aug; 58(2):772-7. PubMed ID: 2960030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H-D-val-leu-lys-aminoisophthalic acid, dimethyl ester, is sensitive to streptokinase-activator not to plasmin.
    Ts'ao C; Galluzzo TS
    Am J Clin Pathol; 1981 Mar; 75(3):372-7. PubMed ID: 6452054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma high molecular weight kininogen concentration in health and in chosen impairments of haemostasis. Evidence that plasmin uncovers a new antigenic site in high molecular weight kininogen.
    Kleniewski J
    Thromb Haemost; 1979 Oct; 42(3):1046-55. PubMed ID: 92069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.